Postgraduate Diploma in Menopause and Andropause
An integrated postgraduate qualification in hormone optimisation across the perimenopausal, postmenopausal and andropausal patient — under the British Menopause Society and British Society for Sexual Medicine frameworks. Six-month hybrid programme for UK primary care.
Status: in development. Year 2 launch target (planned September 2027).
The Acumen PG Diploma in Menopause and Andropause is currently in formal accreditation discussion with the Royal College of General Practitioners CPD Provider Scheme, the British Menopause Society and British Society for Sexual Medicine for educational endorsement, a candidate UK university partner for co-badging, and the NHSE Primary Care Training Hub. UEMS-EACCME European recognition is being pursued in parallel. The sample syllabus below represents the curriculum architecture currently under negotiation. Final structure, accreditation status, and fees will be confirmed before applications open.
Both sides of the hormonal continuum
Most UK postgraduate menopause education focuses exclusively on the female hormonal transition. The Acumen PG Diploma is built on the deliberate decision to address both menopause and andropause as a single integrated curriculum — recognising that the demand for structured testosterone replacement and andropausal optimisation is rising in UK primary care, that the cardiometabolic, sexual and bone-health implications run in parallel across both sexes, and that primary care clinicians supporting middle-aged and older patients need to be confident in both.
The curriculum maps the British Menopause Society 2024 Recommendations and the British Society for Sexual Medicine guidance onto a UK primary care delivery context — taught by faculty whose own clinical practice includes both transdermal HRT and structured testosterone replacement under appropriate frameworks.
For the primary care clinician building hormone-optimisation expertise
UK GPs
Practising GPs with growing menopause and andropause caseloads who want to move beyond symptom management to structured optimisation.
Pharmacist Independent Prescribers
Pharmacist IPs with prescribing scope in HRT and testosterone replacement, working in primary care or specialist menopause clinics.
Nurse Practitioners
Advanced nurse practitioners with menopause caseloads in PCN, GP practice, or specialist clinic settings.
Six modules across six months
Each module runs three to four weeks asynchronously, with one live tutorial mid-module. The cohort meets in person for an opening symposium and a closing case-based assessment.
Module 1 · Foundations of Menopause and Andropause Medicine
The hormonal continuum across midlife. Diagnostic frameworks. BMS 2024 and BSSM recommendations in UK primary care context. Designing a menopause-and-andropause clinic. Information governance and consent.
Module 2 · Perimenopausal Management
Vasomotor and non-vasomotor symptoms. Menstrual disturbance and contraception. Mental health and cognitive aspects. Structured initiation of transdermal HRT. Progestogen choice. Shared decision-making and consent.
Module 3 · Postmenopausal Optimisation
Long-term HRT decisions. Bone health and osteoporosis prevention (with NICE guideline integration). Cardiovascular risk assessment in the postmenopausal patient. Genitourinary syndrome of menopause and vaginal estrogen. Breast health and surveillance.
Module 4 · Andropause and Testosterone Replacement
The clinical biochemistry of male hypogonadism. BSSM framework for testosterone replacement. Formulation choice and monitoring. Cardiovascular safety considerations. Sexual health and erectile dysfunction. Patient selection and shared decision-making.
Module 5 · Cardiometabolic and Bone Implications
The cardiometabolic transition at menopause and andropause. Lipid changes, weight, body composition. Bone density screening and osteoporosis treatment pathway. Integration with cardiometabolic risk reduction (SGLT2i, GLP-1 RA where indicated). Polypharmacy review.
Module 6 · Audit, Service Design, and Final Assessment
Designing a menopause-and-andropause audit in your own practice. Outcome reporting in this domain. Service-evaluation publication pathways. Final case-based assessment and portfolio submission.
Hybrid programme · six months · two cohorts per year
- 80% asynchronous online — modules delivered through a learning management system; structured reading, recorded lectures, discussion forum, weekly quizzes.
- 20% live — six 90-minute interactive webinars (one per module) and one in-person Saturday opening symposium.
- Cohort cadence — September and March (planned, subject to accreditation timing).
- Assessment — modular knowledge checks (30%); audit project from your own practice (40%); final case-based assessment (30%). Portfolio model.
In pursuit, named transparently
- Royal College of General Practitioners CPD Provider Scheme — extension of the DCRM Diploma application; target Year 2.
- British Menopause Society — educational endorsement conversation in development.
- British Society for Sexual Medicine — educational endorsement conversation for the andropause stream.
- UK university co-badging partner — same candidate university as DCRM Diploma.
- NHSE Primary Care Training Hub — endorsement conversation Q1 2027 onward.
- UEMS-EACCME — European CME recognition pursued in parallel.
Faculty
Programme led by Professor Rajesh Varma. Faculty includes invited specialist clinicians from menopause medicine, sexual medicine, endocrinology, and primary care GPwER programmes.
Fees and applications
Indicative fee: to be confirmed once accreditation pathway is finalised. Year 2 indicative range £1,000 - £2,000 per delegate.
Applications: not yet open. Register interest below to receive accreditation confirmation and the application opening date.
Register interest
Be among the first to know when accreditation is confirmed and applications open.
Legal & Disclaimer · enquiry@mdacumen.com